Astellas Pharma Global Development, Inc.

This trial tests an experimental drug called enfortumab vedotin, which is designed to seek out and destroy cancer cells that have a specific protein called Nectin-4 on their surface. The study includes people with metastatic urothelial cancer (a type of bladder cancer) and other …

This phase 3 study tested a new drug, gilteritinib, combined with azacitidine for people with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The participants were adults who could not receive standard intensive chemotherapy. The study compared the combi…

This study checks the long-term safety of an eye injection called avacincaptad pegol for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 278 adults who finished a previous study of this drug will receive the injec…

This study tested an experimental drug called Zimura in 121 people with Stargardt disease, a genetic condition that causes vision loss. Participants received either Zimura injections or a sham procedure. The goal was to see if Zimura could safely slow damage to the retina over 18…

This study tested a new drug called enfortumab vedotin against standard chemotherapy in 608 adults with advanced bladder or urinary tract cancer that had spread or come back after prior treatment. The goal was to see if the new drug helped people live longer and slowed cancer gro…

This study tested a new drug called gilteritinib against standard chemotherapy in 371 adults with a type of acute myeloid leukemia (AML) that has a specific genetic change (FLT3 mutation) and has either come back or not responded to initial treatment. The goal was to see if gilte…

This study tested a new medicine called ASKP1240 in 149 people who received a new kidney. The goal was to see if it could prevent the body from rejecting the kidney as well as or better than current standard treatments. Participants received different combinations of drugs, and r…

This phase 2a study tested an experimental drug called ASKP1240 in 60 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo intravenously. The main goals were to check safety, how the drug moves through the body, and early signs of ef…

This large phase 3 trial tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps men with metastatic hormone-sensitive prostate cancer. Over 1,100 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how lo…

This study tested a new dye called ASP5354 that makes the ureter (the tube from kidney to bladder) glow under a special camera during abdominal surgery. The goal was to help surgeons see the ureter more clearly and avoid accidentally injuring it. About 107 people aged 12 and olde…

This study followed nearly 1,000 menopausal women who were starting a non-hormonal treatment for bothersome hot flashes and night sweats. Researchers tracked how much their symptoms improved after 12 weeks, along with changes in sleep, work productivity, and overall well-being. T…

This study tests whether fezolinetant, a non-hormonal drug, can reduce moderate to severe hot flashes in Chinese women going through menopause. About 150 women will take either fezolinetant or a placebo daily for 12 weeks. The goal is to see if the drug safely eases symptoms, off…

This study tested a dye called ASP5354 that makes the ureter glow under special cameras during abdominal surgery. The goal is to help surgeons avoid accidentally cutting or damaging the ureter, a rare but serious complication. 95 adults with normal or impaired kidney function rec…

This study tested whether a daily pill called ASP8062 can reduce pain and improve daily life for people with fibromyalgia. 183 adults took either the drug or a placebo for 8 weeks. Researchers measured pain scores, side effects, and overall well-being. The trial is now complete, …